On June 9, 2025, Lyell Immunopharma, Inc. increased its Board size from seven to eight members and appointed Mark Bachleda as a Class I director, with his term expiring in 2028. He will receive cash and equity compensation as per the company's policy, which was adjusted for a recent reverse stock split.